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ABSTRACT
Several classification systems have been proposed to address genomic 
heterogeneity of glioblastoma multiforme, but they either showed limited prognostic 
value and/or are difficult to implement in routine diagnostics. Here we propose a 
prognostic stratification model for these primary tumors based on tumor gene 
amplification profiles, that might be easily implemented in routine diagnostics, and 
potentially improve the patients management. Gene amplification profiles were 
prospectively evaluated in 80 primary glioblastoma multiforme tumors using single-
nucleotide polymorphism arrays and the results obtained validated in publicly available 
data from 267/347 cases. Gene amplification was detected in 45% of patients, and 
chromosome 7p11.2 including the EGFR gene, was the most frequently amplified 
chromosomal region – either alone (18%) or in combination with amplification of 
DNA sequences in other chromosomal regions (10% of cases). Other frequently 
amplified DNA sequences included regions in chromosomes 12q(10%), 4q12(7%) and 
1q32.1(4%). Based on their gene amplification profiles, glioblastomas were subdivided 
into: i) tumors with no gene amplification (55%); ii) tumors with chromosome 
7p/EGFR gene amplification (with or without amplification of other chromosomal 
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regions) (38%); and iii) glioblastoma multiforme with a single (11%) or multiple 
(6%) amplified DNA sequences in chromosomal regions other than chromosome 7p. 
From the prognostic point of view, these amplification profiles showed a significant 
impact on overall survival of glioblastoma multiforme patients (p>0.001). Based on 
these gene amplification profiles, a risk-stratification scoring system was built for 
prognostic stratification of glioblastoma which might be easily implemented in routine 
diagnostics, and potentially contribute to improved patient management.
INTRODUCTION
Primary glioblastoma multiforme (GBM) is the 
most common and malignant subtype of glial tumors 
[1]. From the clinical and biological point of view, 
GBM includes a rather heterogeneous group of tumors 
that vary by site of origin, histophatological features, 
tumor microenvironment [2] and genetics [3]. They are 
usually resistant to radio/chemotherapy and show overall 
survival (OS) rates of a few months to years, making them 
unvariably lethal [4, 5]. Criteria used for the histological 
classification and grading of GBM have been recently 
revised in the 4th World Health Organization (WHO) 
classification of GBM [1]; however, this classification still 
fails in distinguishing subgroups (or variants) of primary 
GBM that display clearly distinct clinical and biological 
behaviours, despite sharing similar histopathological 
features [6–9].
Besides histopathology, molecular genetics data 
has also confirmed the high heterogeneity of GBM, 
both at the intertumoral and intratumoral levels [3, 10–
12]; in addition, molecular genetics data also proved 
useful for improving the diagnosis, classification, and 
prognostic stratification of GBM [13, 14], with therapeutic 
implications [14–16]. However, despite all advances 
achieved via the study of the methylation status, gene 
mutations (e.g. IDH1 or PT53 genes) [17] and affected 
oncogenic pathways [11, 18–20], the precise mechanisms 
involved in the pathogenesis of GBM still remain far from 
being fully understood. In turn, routine implementation 
of molecular genetics into the diagnostic classification of 
GBM still remains limited, due to the complexity of the 
genetic findings involved.
Among other genetic abnormalities, the copy 
number aberration (CNA) profile of tumor cells, over 
the copy number variation (CNV) of individual patients, 
has been recognized [21–24] as a useful prognostic tool 
in GBM [14]. Thus, some copy number aberrations 
involving one or multiple genes that affect a significant 
fraction of the tumors, (e.g. CNA associated with either 
gains of chromosome 7 and/or amplification of the 
epidermal growth factor receptor (EGFR) gene [18], 
and losses of DNA sequences in chromosome 10 [19], 
together with other less frequent alterations involving 
DNA sequences in chromosomes 12q13-15 [25], 4q and 
1q [26], have all been associated with the outcome of 
GBM patients. Despite this, risk stratification of GBM 
into classical and non-classical GBM, based on gene 
expression profiling (GEP) data, was first proposed 
[27]. Later on, Phillips et al [13] defined three molecular 
subtypes of GBM according to a combination of GEP 
data and numerical alterations of chromosomes 7 and 
10: proneural, proliferative and mesenchymal GBM. 
This classification was subsequently redefined by the 
Cancer Genome Atlas Consortium (TCGA) [14] into 
four subtypes – proneural, proliferative, mesenchymal 
and neural GBM, using a combination of GEP data and 
CNA, together with the pattern of somatic mutations. 
Despite overlapping data is used in the later two 
classifications, both approaches are not equivalent, at 
the same time they are rather complex to be reproducibly 
applied in routine laboratory diagnostics. In addition, 
the prognostic impact of both approaches remains 
controversial because e.g. the proneural subgroup 
of Philips [13] has a longer survival, while proneural 
tumors defined according to the TCGA classification 
[14], have a poorer outcome. In turn, despite EGFR 
amplification is a defining event for the classical 
subtype of GBM, in the TCGA classification it appears 
in >95% of the neural and mesenchymal tumor subtypes, 
but also in 54% of the proneural subtype; similarly, the 
same EGFR mutations (e.g. the EGFRvIII variant) can 
also be detected across all above subtypes of GBM; in 
addition, neither the criteria used to define the proneural 
class based on focal amplification of the 4q12 locus 
harboring the PDGFRA gene (with or without EGFR 
amplification), nor the evaluation of the expression of 
the NEFL, GABRA1, SYT1 and SLC12A5 genes, are 
currently applied for routine diagnostic classification 
of GBM. Altogether this hampers fast and reproducible 
risk-stratification of GBM patients at diagnosis, based 
on this classification.
Here we investigated the gene amplification 
profiles (GAP) across the whole tumor genome of a 
series of 80 GBM tumors, as detected by high-density 
single-nucleotide polymorphism (SNP)-arrays, and 
evaluated their impact on overall survival (OS) of GBM 
patients. Based on the results obtained, a GAP-based risk-
stratification model was built and validated in a series of 
267 GBM tumors from a total of 7 GBM series publicly 
available at the GEO and ArrayExpress databases and/or 
whose data was kindly provided by the authors [15, 24, 
28–32], in addition to our own cases.
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RESULTS
Gene amplification profiles and chromosomal 
regions involved in GBM
SNP-arrays showed CNA containing > 7 DNA 
copies of the same DNA sequence for ≥1 chromosome/
chromosomal region in all (80/80) cases analyzed from 
series 1. In the majority of patients (45/80; 56%) such 
CNA involved genetic amplification of DNA sequences 
from ≥1 chromosomal region (Table 1 and Figure 1). 
As expected, DNA sequences at chromosome 7p11.2 
containing the EGFR gene, were the most frequently 
amplified sequences (30/80 cases; 38%), followed by 
DNA sequences at the 12q (14/80; (18%), 4q (8/80; 10%) 
and 1q (5/80; 6%) chromosomal regions.
Amplification of DNA sequences at chromosome 
7p11.2 was found either alone (17/80; 21%) or in 
combination with amplification of DNA sequences at 
other regions in chromosomes 1q, 4q, 5q, 6q, 11p, 11q, 
12q, 17p and 17q (13/80; 16% of cases) (Table 1). The 
most frequent combination of simultaneously amplified 
DNA sequences at chromosomal regions involving 7p11.2 
were those of 7p and 12q (7/80 cases; 9%) and of 7p and 
11p (2/80 cases; 3%) (Table 1).
Isolated amplification of DNA sequences at 
chromosomal regions other than 7p11.2 was found in 
10/80 cases (13%); this included isolated amplification of 
4q12 (where the PDGFRA gene is coded) in 4/80 cases 
(5%), 12q14.1 (where the CDK4 gene is coded) in 3/80 
cases (4%), 1q32.1 (this chromosomal region contains the 
MDM4 gene) in another 2/80 tumors (3%) and 16q in one 
tumor (1%) without any annotated gene being coded in 
the amplified DNA sequences from this later chromosomal 
region (Table 1).
In turn, genetic amplification at 12q was detected 
in 14/80 cases (18%) including isolated amplification in 
3 GBM and combined 12q gene amplification with gene 
amplification at other chromosome regions (1p, 1q, 4q, 
11p, 11q, 7q, or 17q) in 11 tumors (Table 1), including 
amplification at chromosome 7p in 7 cases (9%). Gene 
amplification at 4q was found in 8/80 cases (10%) either 
alone (4/80; 5% or in association with amplification 
of DNA sequences at the 12q and/or 7p (4/80; 5%) 
chromosomal regions (Table 1).
Overall, coexistence of genetically amplified DNA 
sequences at ≥ 2 chromosomal regions in the same tumor 
(median of 2 altered chromosomal regions; range: 2-4 
regions) was found in 18 cases (23%). In 13 of these 18 
tumors, the EGFR gene was involved (Table 1). Of note, 
gene amplification involving regions at chromosomes 
7q (4%), 11p (3%), 17q (3%), 5q (1%), 6q (1%), 11q 
(1%) and 17p (1%) included variable chromosomal 
patterns and numbers of genes involved (Table 1 and 
Table 2). Although gene amplification was frequently 
associated with chromosomal gains (polyploidy), there 
were also cases with polyploidies in the absence of gene 
amplification and vice versa.
Tumors with isolated amplification of DNA 
sequences at a single chromosomal region had a median 
of 9 genes involved (range: 1 to 40 genes). Gene 
amplification at 7p11.2 included the smallest number 
of affected genes (median: 5 vs 16 genes for gene 
amplification involving DNA sequences at chromosomes 
12q, 1q and 4q). In turn, cases showing amplified 
DNA sequences at several chromosomal regions had 
a median of 19 genes involved (range: 1 to 45 genes). 
The most commonly (>5% of cases) amplified genes per 
chromosomal region included: i) 9 genes at chromosome 
1q32.1 (SOX13, ETNK2, REN, KISS1, GOLT1A, 
PLEKHA6, PIK3C2B, MDM4 and LRRN2); ii) 4 genes at 
chromosome 4q12 (SCFD2, FIP1L1, PDGFRA and KIT); 
iii) 5 genes in chromosome 7p11.2 (EGFR, LANCL2, 
VSTM2A, VOPP1 and SEC61G), and; iv) multiple genes 
at chromosome 12 which had 3 cytobands involved, i.e. 
12q14.1 (CDK4, METTL1, CYP27B1, AVIL, CTDSP2, 
METT21B, AGAP2, OS9, TSFM), 12q13.3 (B4GALNT1, 
KIF5A, PIP4K2C, DTX3, SLC26A10, MARS, DCTN2, 
ARHGEF25) and 12q15 (ATP23, MDM2, CPM) (Table 
3). When individually considered, the EGFR gene (38%) 
together with the LANCL2 gene (23%), coded also at 
chromosome 7p11.2, were the two most frequently 
amplified genes (Table 3). Of note, amplification of none 
of the genes detected here had been previously described 
in healthy individuals [33] and/or publicly available GBM 
databases.
Classification of GBM tumors based on their 
gene amplification profiles (GAP)
Based on the presence of gene amplification, their 
specific subtype and the number of chromosomal regions 
affected by gene amplification (Figure 1), GBM tumors 
from group 1 (series 1) were divided into five different 
subgroups: i) tumors which had no gene amplification 
(n=35; 44%); ii) tumors with isolated amplification of 
DNA sequences at chromosome 7p including the EGFR 
gene (n=17; 21%); iii) GBM with isolated amplification 
of DNA sequences at a chromosomal region different 
from chromosome 7p (n=10; 13%); iv) tumors with 
amplifications of DNA sequences from multiple (≥2) 
chromosomal regions including that of the EGFR gene 
(n=13; 16%), and; v) tumors with amplification of DNA 
sequences at ≥2 chromosomal regions which did not 
include amplification of the EGFR gene (n=5; 6%) (Table 
4 and Figure 2).
The above GAP were further investigated in the other 
7 series of GBM used for validation purposes, for a total of 
267 primary GBM patients (Table 4). Around half of these 
cases ˗156/267 (58%)˗ did not show genetic amplification 
at any of the chromosomal regions investigated (Table 4); 
in contrast, 69 (26%) tumors had gene amplification at 
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Table 1: Major subsets of GBM that carried different gene amplification profiles, as identified in our series (series 
1) of GBM patients (n=80) grouped according to the location, type and number of chromosomal regions involved 
(n=45/80 tumors)
Tumor group Tumor ID Amplified chromosome(s)
N. of amplified 
chromosomal 
band(s)/genes
Amplified Chromosomal bands
Gene amplification at a 
single chromosomal region
(n=27)
EGFR gene involved 
(n=17;21%)
G94
7p
2/4 7p11.2/7p12.1#
G55 2/2
G91 1/2
7p11.2
G80 1/3
G72 1/2
G68 1/2
G67 1/1
G56 1/2
G44ϑ 1/3
G40ϑ 1/3
G37ϑ 1/2
G30ϑ 1/1
GBM3ϑ 1/17
GBM7ϑ 1/3
GBM11ϑ 1/7
GBM12ϑ 1/25
GBM17ϑ 1/2
EGFR gene not 
involved (n=10;13%)
G73
4q
3/35 4q11/4q12/4q13.3
G12 1/29 4q11#/4q12
GBM1ϑ 1/16 4q12
GBM14ϑ 1/7 4q12
G51ϑ
12q
2/14 12q13.3/12q14.1
G46ϑ 2/5 12q14.1-q14.3/12q15
G25ϑ 1/8 12q14.1
G79
1q
1/12 1q32.1
G54 1/18
G10 16q# 1/0 16q12.1-q12.2
Gene amplification at 
multiple
chromosomal
regions
(n=18)
EGFR gene & other 
amplicons involved 
(n=13;16%)
G39ϑ 7p, 12q 1/2, 2/9 7p11.2/12q13.3/12q14.1
G41 1/4, 2/11 7p11.2/12q14/12q15
G53ϑ 3/6, 1/2 7p11.2/7p21.3/7p22.1/12q15
G70 1/1, 2/20 7p11.2/12q13.3/12q14.1
G83 1q, 7p 1/16, 1/1 1q32.1/7p11.2
G65 1/26, 1/12
GBM19ϑ 7p, 7q 4/5 7p21/7p12.3/7p11.2/7q22.3
G23ϑ 7p, 11p 1/2, 1/17 7p11.2/11p13
GBM4ϑ 1q,7p,12q 1/18, 1/6, 2/11 1q32.1/7p11.2/12q13.3/12q14.1
G82 4q, 7p, 12q 2/6, 1/1, 3/23 4q12/4q13.3/7p11.2/12q13.12- q13.13/12q13.3/12q14.1/12q15
G90 5q#, 6q#, 7p 1/1 5q34/6q25/7p11.2
G81 7p, 17p, 17q 1/2, 2/11 7p11.2/17p13.1/17q25.1
G71 7p, 11p, 11q, 12q 2/5, 3/16, 2/19 7p11.2/7p12.1/11p15.3/11p11.2
#/ 
11q13.3/11q25/12q13.3/12q14.1
(Continued )
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chromosome 7p11.2 amplification –46/267 cases (17%) with 
isolated EGFR amplification and 23/267 cases (9%) showed 
amplification of DNA sequences at multiple chromosomal 
regions including amplification of the EGFR gene– (Table 
2 and Table 4). Similarly to what was observed in the test 
series, gene amplification at 7p, in association with gene 
amplification at chromosome 12q, was found in 6 tumors 
(2%) and gene amplification at chromosome 7p together 
with amplification of DNA sequences at chromosomal 
regions other than 12q was found in another 17 cases (6%), 
–e.g. gene amplification at the 1q or 4q chromosomal 
regions in 3/267 (1.1%) and 4/267 (1.5%) cases, 
respectively, and at 7q or 3q in 3/267 (1.1%) and 2/267 
(0.8%) tumors, respectively – (Table 2). DNA sequences 
from other chromosomal regions which were also found to 
be amplified at lower frequencies than those amplified at 7p, 
included DNA sequences at chromosomes 12q (10/267; 4%) 
and 4q (6/267; 2%) (Table 2). Genetic amplification at other 
chromosomal regions such as 7q, 12p and 13q was found in 
two tumors each, and gene amplification at the 6p, 8q, 15q 
and 17q chromosomal regions was found in a single tumor 
each (Table 2).
Upon merging the test and validation series (series 
1 to 8), the following distribution into the 5 subgroups of 
GBM defined by their distinct GAP (Table 4), was found: 
191 cases (55%) had no gene amplification (group 1), 
63/347 cases (18%) showed isolated amplification of EGFR) 
(group 2); 37/347 (11%) displayed isolated amplification of 
genes other than EGFR (group 3); 36/347 (10%) had genetic 
amplification at multiple chromosomal regions, including 
amplification of the EGFR gene (group 4); and 20/347 (6%) 
showed multiple amplified DNA sequences at ≥ 2 distinct 
chromosomal regions, which did not include amplification 
of the EGFR gene (group 5) (Table 4).
Prognostic impact of gene amplification profiles 
in GBM
From the prognostic point of view, the above 
defined GAP showed a significant impact on OS of 
GBM patients, both in the test series (series 1) alone 
(p<0.001; Figure 3A), and in the whole cohort (series 1-8; 
p<0.001) (Figure 3C). In detail, cases that did not show 
gene amplification or that displayed amplification of the 
EGFR gene (alone or in combination with amplification of 
genes in other chromosomal regions) (groups 1, 2, and 4, 
respectively) showed a significantly better outcome than 
patients with isolated amplification of genes other than 
the EGFR gene (group 3) and cases with amplification 
of multiple chromosomal regions which did not involve 
the EGFR region (group 5): median OS of 14, 18 and 14 
months vs 6 (p=0.001, p<0.001 and p=0.007, respectively) 
and 8 months (p=0.03, p<0.001 and p=0.003, respectively) 
in the test series alone, and of 14, 18 and 14 months vs 
8 (p=0.03, p=0.003 and p=0.16, respectively) and 8 
(p<0.001, p<0.001 and p=0.001, respectively) months in 
the whole cohort, respectively (Figure 3, panels A and C, 
respectively). When cases were re-grouped according to 
i) the absence of gene amplification or presence of EGFR 
gene amplification vs ii) occurrence of other GAP, the 
prognostic impact of the re-grouped GAP was enhanced, 
both when the test series alone and the whole cohort of 
patients analyzed, were considered: median OS rates of 15 
vs 6 months (p< 0.001) and of 15 vs 8 months (p<0.001), 
respectively (Figure 3 panels B and D, respectively). 
Subsequent multivariate analysis of prognostic factors 
showed that the tumor GAP (p<0.001), together with the 
administration of chemotherapy (p<0.001) were the best 
combination of independent prognostic factors to predict 
patient OS (Table 5).
DISCUSSION
Despite histopathology remains the gold standard 
for the diagnosis of GBM, it provides limited information 
about patient outcome. Consequently, new classifications 
have been proposed in recent years for GBM in which 
molecular genetics data derived from chromosomal 
alteration profiles, DNA mutational status and GEP 
data, is used for the definition of tumor subgroups of 
Tumor group Tumor ID Amplified chromosome(s)
N. of amplified 
chromosomal 
band(s)/genes
Amplified Chromosomal bands
EGFR gene
not involved
(n=5;6%)
GBM13ϑ
4q, 12q
1/7, 1/11 4q12/12q14.1
GBM22ϑ 1/19, 2/20 4q12/12q13.3/12q14.1
G08ϑ 1p, 7q 3/30, 1/7 1p12/1p13/1p21/7q21.2-q21.3
G88 4q, 7q, 12q 2/13, 1/3, 4/30 4q12/4q13.3/7q31.2/12q13.3/12q14.1/12q15/12q21.1
G89 1p, 12q, 17q 1/3, 2/21, 3/6 1p36.21/12q13.3/12q14.1/17q11/17q12
#/17q2
1/17q22#/17q24
ID: Case identification code. Most frequently involved genes per chromosomal band included: 1q32.1, MDM4; 4q12, PDGFRA; 12q14.1, CDK4; 12q15, MDM2; 7q31.2,MET. #: 
Amplified chromosomal region without any annotated gene in it; ϑ: EGFR gene mutation studied in this sample.
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Figure 1: Illustrating examples of the cytogenetic profiles representative of the distinct patterns of gene amplification identified in 
GBM tumors from series 1, used for the definition of the 5 different subgroups of GBM based on their gene amplification profiles.
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Table 2: Frequency of genetic amplification involving different chromosomal regions in the test (series 1) vs the 
validation series (series 2-8) of GBM patients analyzed
Number of amplified regions Chromosomal regions involved
Amplified GBM cases
Series 1
n=45/80 (56%)
Series 2-8
n=111/267 (42%)
One
chromosomal region amplified
(n=100; 29%)
7p
12q
4q
1q
12p
7q
13q
6p
8q
15q
16q
17q
17 (21%)
3 (4%)
4 (5%)
2 (3%)
(0)
(0)
(0)
(0)
(0)
(0)
1(1.2%)
(0)
46(17%)
10 (4%)
6 (2%)
1 (0.4%)
2 (0.8%)
2 (0.8%)
2 (0.8%)
1 (0.4%)
1 (0.4%)
1 (0.4%)
(0)
1 (0.4%)
Subtotal 27 (34%) 73 (27%)
Two
chromosomal regions amplified
(n=39; 11%)
7p,12q 
1q,7p
1q,4q
7p,7q
3q,7p
4q,7p
4q,12q 
1q,5p
1p7q
2q,12q
4q,9p
5p,7p
5q,7p
7p,11p
7p,9p
7p,14q
7p, Xp
17q,20q
20p,20q
4 (5%)
2 (3%)
(0)
1 (1.2%)
(0)
(0)
2 (3%)
(0)
1 (1.2%)
(0)
(0)
(0)
(0)
1 (1.2%)
(0)
(0)
(0)
(0)
(0)
4 (1%)
3 (1%)
3 (1%)
2 (0.8%)
2 (0.8%)
2 (0.8%)
2 (0.8%)
1 (0.4%)
(0)
1 (0.4%)
1 (0.4%)
1 (0.4%)
1 (0.4%)
(0)
1 (0.4%)
1 (0.4%)
1 (0.4%)
1 (0.4%)
1 (0.4%)
Subtotal 11 (14%) 28 (10%)
≥Three
chromosomal regions amplified
(n=17; 5%)
1p,1q,10q
1p,7p,12q
1p,12q,17q
1q,7p,12q
4p,4q,12p
4q,7p,12q
4q,7q,12p
4q7q12q
4q,7p,18q
5q,6q,7p
6p,7q,12q
7p,17p,17q
2p,7p,12p,12q
4q,7p,7q,15q
7p11p11q12q
7q,12q,17q,20q
1p,4p,7p,11q,14q
(0)
(0)
1 (1.2%)
1 (1.2%)
(0)
1 (1.2%)
(0)
1 (1.2%)
(0)
1 (1.2%)
(0)
1 (1.2%)
(0)
(0)
1 (1.2%)
(0)
(0)
1 (0.4%)
1 (0.4%)
(0)
(0)
1 (0.4%)
(0)
1 (0.4%)
(0)
1 (0.4%)
(0)
1 (0.4%)
(0)
1 (0.4%)
1 (0.4%)
(0)
1 (0.4%)
1 (0.4%)
Subtotal 7 (9%) 10 (4%)
Results expressed as number (percentage) of cases showing gene amplification/chromosome arm.
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Table 3: Frequency and chromosomal localization of recurrently amplified genes (> 5% of cases) in GBM from 
series 1 (n=45/80 tumors), and other previously reported series of GBM (n=111/267 tumors) as detected by SNP-
arrays
Amplified genes
Amplified chromosomal regions
Symbol
Frequency of gene 
amplification
Chr Amplified/Total cases
(%)
Cytoband Series 1
(n=45)
Series 2-8
(n=111)
Chr 7 119/347
(34%)
7p11.2 EGFR
LANCL2
VSTM2A
VOPP1
SEC61G
67%
40%
31%
27%
11%
57%
19%
29%
7%
19%
Chr 12 34/347(10%)
12q14.1 CDK4
CYP27B1
METTL1
AVIL
CTDSP2
METT21B
AGAP2
OS9
TSFM
29%
29%
27%
27%
27%
22%
22%
16%
16%
14%*
2%*
14%*
18%*
2%*
16%*
16%*
2%*
-
12q13.3 B4GALNT1
KIF5A
PIP4K2C
SLC26A10#
DTX3
MARS
ARHGEF25
DCTN2#
16%
11%
11%
11%
9%
9%
9%
7%
14%*
10%*
-
-
12%*
4%*
4%*
-
12q15 ATP23
MDM2
CPM
16%
9%
9%
14%*
12%
11%
Chr 4 26/347
(7%)
4q12 SCFD2
FIP1L1
PDGFRA
KIT
18%
18%
18%
7%
7%
14%
10%
10%
Chr 1 14/347
(4%)
1q32.1 SOX13
ETNK2
REN
KISS1
GOLT1A
PLEKHA6
PIK3C2B
MDM4
LRRN2
11%
11%
11%
11%
11%
11%
11%
11%
9%
5%
3%
2%
3%
3%
5%
5%
3%
2%
#genes included in the SNP6 array; *The incidence of amplified genes localized in the 12q14.1, 12q13.3 and 12q15 
cytobands was calculated using only the 250k-SNP_Nsp and/or STY arrays (n=50) due to the absence of probes for these 
specific genes in the 50k array.
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Table 4: Overall survival and genetic features of GBM patients from our series (series 1; n=80) and the seven series 
of GBM patients previously reported in the literature (series 2-8; n=267) and included in this study for a total of 347 
GBM investigated
Variables
GBM patient series
Series 1
Crespo 
et al.*
(GSE
42631)
Series 2
Chen et 
al.
(GSE
19612)
Series 3
Beroukhim 
et al.
(GSE19399/ 
GSE9635)
Series 4
Bralten 
et al.
NA
Series 5
Hodgson 
et al.
(GSE
14804)
Series 6
Yin et al.
(EMEXP-1330)
Series 7
Kuga et 
al.
(GSE 
10922)
Series 8
Solomon 
et al.
(GSE
13021)
Total N. of cases
(n=347) 80 24 120 15 12 53 13 30
N. of cases with
annotated OS
(n=273)
80 24 104 15 NA 50 NA NA
Median OS
months (range)
15
(0-83)
15
(1-31)
18
(1-67)
10
(4-28) NA
17
(0-90) NA NA
N. of SNP probes 
investigated 5-18x10
5 5x105 1-2.5x105 2.5x105 0.5x105 0.5-2.5x105 0.5x105 2.5x105
New 
genetical 
subsets
NO gene AMP
(n=191; 55%)
35
(44%)
11
(46%)
75
(62%)
9
(60%)
7
(58%)
31
(58%)
7
(54%)
16
(53%)
Isolated 
EGFR AMP
(n=63; 18%)
17
(21%)
7
(29%)
20
(17%)
1
(7%)
2
(17%)
10
(19%)
2
(15%)
4
(13%)
Isolated non-
EGFR AMP
(n=37; 11%)
10
(13%)
1
(4%)
11
(9%)
3
(20%)
2
(17%)
7
(13%)
1
(8%)
2
(7%)
Multiple AMP 
including 
EGFR
(n=36; 10%)
13
(16%)
3
(13%)
8
(7%)
1
(7%) 0
3
(6%)
2
(15%)
6
(20%)
Multiple AMP 
without EGFR
(n=20; 6%)
5
(6%)
2
(8%)
6
(5%)
1
(7%)
1
(8%)
2
(4%)
1
(8%)
2
(7%)
* 23 additional GBM tumors not available in the GEO data repository were hybridized with the Cytoscan750K (n=11 
samples) and Cytoscan HD (n=12 samples) SNP-arrays; AMP: genetic amplification; GAP: genetic amplification profile; 
GSE: genomic repository series code; OS: overall survival; N: number; NA: not available.
distinct embryonic tissue origins [13, 14]. However, these 
classification models are difficult to implement in routine 
diagnostics and/or remain of relatively limited prognostic 
value [34–36].
Among other cytogenetic/molecular alterations, 
gene amplification, particularly gene amplification 
involving the EGFR gene, represents one of the most 
common genetic changes in GBM [11, 20-22, 37]. Thus, 
EGFR amplification at chromosome 7p11.2 can be found 
in between one third and half of all GBM patients as 
the only chromosomal region amplified – including a 
variable number of amplified genes – or it can be find 
in the same tumor in combination with amplification of 
genes located at other chromosomal regions, such as the 
MDM2, MDM4, PDGFRA and CDK4 genes encoded in 
chromosomes 12q15, 1q32.1, 4q12 and 12q14.1 [11, 14, 
38], respectively. Of note, gene amplification is a common 
genetic alteration across different malignancies and it 
usually involves (wild-type or mutated) genes that show 
oncogenic potential (i.e are capable of reproducing the 
tumor); thereby, it might confer a malignant phenotype 
associated with a variable outcome, depending on the 
specific genes amplified and/or overexpressed. Despite 
this, no study has been reported so far in which the impact 
of different GAP on OS has been investigated in a large 
series of GBM patients.
Here we investigated the GAP across the whole 
GBM tumor genome and analyzed their impact on 
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patient OS, based on one of the largest series of GBM 
patients reported so far in the literature. SNP-arrays were 
used for both sensitive identification of CNA involving 
specific DNA sequences across the whole tumor genome 
and detailed delineation of the amplified genes; in 
order to avoid CNV due to germinal single nucleotide 
polymorphisms, insertions and deletions potentially 
associated with an increased predisposition to GBM 
Figure 2: Distribution of the most frequently altered chromosomes (A) and chromosomal regions (B) showing isolated or multiple 
amplifications both in cases from series 1 (n=45/80) and in patients (111/267) from the seven distinct series previously reported in the 
literature by others. Results are shown as percentage values from all cases analyzed.
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Figure 3: Prognostic impact on overall patient survival of distinct gene amplification profiles of GBM patients from the test cohort – series 
1 alone (n=76); panels (A) and (B) – and after pooling our cases with 181 additional cases from seven series of GBM patients previously 
reported in the literature by other groups (panels (C) and (D); n= 257 GBM). In panels (A) and (C), GBM patients were grouped as 
having i) no gene amplification; ii) isolated EGFR amplification; iii) gene amplification at multiple chromosomal regions including EGFR 
gene amplification; iv) isolated amplification of DNA sequences from a single chromosomal region other than 7p11.2 (i.e not including 
amplification of the EGFR gene), and; v) gene amplification at multiple chromosomal regions in the absence of EGFR amplification. In 
panels (B) and (D), patients were grouped as: i) cases showing either no gene amplification or having EGFR gene amplification and ii) 
patients showing genetic amplification at one or more chromosomal regions which did not involve the EGFR gene. Median overall survival 
is expressed in months and was calculated for 257 patients from series 1-8. Cases who were alive but had a follow-up of less than 18 months 
and/or died within the 1st month after surgery (n= 16) were excluded from OS analyses.
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(e.g. the rs1801320 SNP in the RAD51 DNA repair gene 
[39]), paired tumor and peripheral blood (PB) samples 
were analyzed per patient.
Overall, our results showed the presence of 
gene amplification in the majority (>50%) of tumors 
investigated. As expected, genetic amplification 
involving DNA sequences at the 7p11.2 chromosomal 
region was by far the most frequent alteration, followed 
by genetic amplification at the 12q, 4q12 and 1q32.1 
chromosomal regions, and to a lower extent also, at 1q, 
5q, 6q, 7q and at regions in both arms of chromosomes 
11 or 17. These results confirm and extend on previous 
observations by our [20–22] and other groups [40, 
41] which indicate that EGFR is the most frequently 
amplified oncogene in GBM, where it is detected 
in up to 40% of primary GBM tumors in association 
Table 5: Clinical characteristics of the GBM patients included in the series 1 (n=76) and their association to disease 
outcome
Clinical/genetic characteristics Patient distribution
Overall survival
Univariate analysis Multivariate analysis
Median 
(range) p-value
Hazard 
Ratio (95% 
CI)
p-value
Age >30 2 (2%) 67 (2.7-67) <.001
31-45 9 (12%) 15 (8-21)
46-60 21 (28%) 14 (2-63)
61-75 34 (45%) 13 (2-83)
>75 10 (13%) 6 (2-11)
Karnofsky Index # >70 48 (64%) 15 (2-83) .004
≤70 27 (36%) 10 (2-30)
Type of Surgery Complete resection 24 (32%) 15 (2-83) .012
Partial resection 41 (54%) 13 (2-67)
No resection 11 (14%) 6 (2-21)
Adjuvant 
chemotherapy#
Stupp 43 (67%) 18 (2-83) <.001 3 (2-4) <.001
BCNU 10 (16%) 13 (5-67)
No chemotherapy 11 (17%) 6 (2-11)
Gene amplification 
profile
No gene AMP 34 (45%) 13 (2-67) <.001
Isolated EGFR AMP 16 (21%) 17 (9-83)
Multiple AMP 
including EGFR 12 (16%) 13 (2-29)
Isolated non-EGFR 
AMP 9 (12%) 6 (2-15)
Multiple AMP without 
EGFR 5 (6%) 8 (2-9)
No gene AMP+EGFR 
AMP 62 (82%) 14 (2-83) <.001 6 (2-12) <.001
AMP without EGFR 14 (18%) 6 (2-15)
CI: confidence interval; #: Data of Karnofsky index and adjuvant chemotherapy were only available in only 75 and 65 GBM 
patients respectively; Stupp: radiotherapy plus temozolamide; BCNU: carmustine; AMP: genetic amplification.
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with a better outcome, compared to cases that show 
either no gene amplification or amplification of genes 
other than EGFR [20, 37]. At present, it is well-
established that activation of the EGFR gene via gene 
amplification and/or mutations, up-regulates the RAS/
RAF/MAPK and PI3K signaling pathways, translating 
into a tumor phenotype consisting of: i) abnormally 
high cell proliferation and ii) survival of tumor cells, 
and iii) an increased angiogenesis [11, 42]. Of note, 
here we confirm via mapping of the amplified region 
in chromosome 7p11.2, that this alteration frequently 
includes also the LANCL2 gene, in addition to other 
genes adjacent to the EGFR and LANCL2 genes [20, 
43]. Although the LANCL2 gene codes for a protein 
involved in up-regulation of AKT and cell survival, and 
an increased cell sensitivity to adriamycin [44, 45], its 
precise mechanism of action remains elusive.
In line with previous observations [11, 38, 46], 
EGFR gene amplification at the 7p11.2 chromosomal 
region, was found either as the only amplified DNA 
sequence, or in association with amplification of DNA 
sequences at other chromosomal regions and genes such 
as the PDGFRA, MDM2, MDM4 and CDK4 genes. 
Such combined pattern of amplification of multiple 
genes at distinct chromosomal regions might lead to 
unique malignant transformation profiles for which 
the underlying mechanisms are still poorly understood; 
however, in our series, it did not prove to confer a 
more adverse outcome vs isolated amp 7p11.2. In 
contrast, isolated amplification of DNA sequences at 
chromosomal regions other than that containing the 
EGFR gene, were associated with a significantly shorter 
OS of GBM patients. Of note, these later alterations 
most frequently affected genes encoded in the 12q, 
4q and 1q chromosomal regions, and they typically 
involved multiple genes [15]. Thus, amplification of 
DNA sequences at the 12q13-14 chromosomal region 
usually included the CDK4 gene together with the 
METTL1, CYP27B1, AVIL, CTDSP2, METT21B, AGAP2 
and OS9 genes, while genetic amplification at 12q15 
affected the MDM2 oncogene in a significant fraction 
of all (primary) GBM tumors analyzed. CDK4 is a 
member of the Ser/Thr protein kinase family, required 
for the cell cycle transition from the G1 to S-phase 
[47]; thus, CDK4 phosphorylates the Rb gene product 
leading to its inactivation and the release of proteins 
required for cell cycle progression, at the same time 
it also down-regulates TP53 [47]. In turn, AVIL binds 
actin and promotes the development of neuronal cells, 
while the MDM2 gene codes for a nuclear-localized E3-
ubiquitin ligase whose transcription is recognized as the 
main p53 negative regulator [48]. In our series, genetic 
amplification at the 4q11-12 chromosomal region, 
systematically affected the PDGFRA gene together with 
the SCFD2 and FIP1L1 genes. PDFGRA [11] codes for a 
tirosine-protein kinase cell surface receptor of the PDGF 
growth factor, which promotes cell proliferation and 
migration. Finally, amplification of DNA sequences at 
chromosome 1q32.1 involved the MDM4 gene together 
with the SOX13, ETNK2, KISS1, GOLT1A, PLEKHA6, 
REN and PIK3C2B genes. MDM4 inhibits TP53 and 
TP73, mediating cell cycle arrest via binding to their 
transcriptional activation domain, at the same time it 
inhibits degradation of MDM2 [48], whereas PIK3C2B 
belongs to the PI3K gene family and activates signaling 
for cell proliferation, survival and migration [49]. In 
turn, the DTX3 ubiquitin ligase gene probably acts both 
as a positive and negative regulator of Notch, depending 
on the developmental stage and cell context [50].
Altogether, these findings indicate that the distinct 
GAP here reported for GBM tumors might confer a 
distinct biological and (also) clinical behavior to these 
tumors. Thus, based on the presence vs absence of gene 
amplification and its subtypes, five different patterns 
were defined among our GBM patients, which showed 
an association with OS. From the prognostic point of 
view, these five GAP could be further re-grouped into 
two major risk-groups including: i) patients with either 
no gene amplification or EGFR gene amplification 
associated with or without amplification of genes coded 
at chromosomal regions other than chromosome 7p11.2, 
with a significantly longer OS; and, ii) cases presenting 
with amplification of one or more chromosomal regions 
that did not include EGFR gene amplification, and that 
were associated with a significantly poorer outcome. The 
prognostic impact of this later classification was further 
confirmed in a larger cohort of GBM patients previously 
reported in the literature and, together with the type of 
treatment administered, emerged as the most powerful 
combination of independent prognostic factor for GBM 
patients. However, the precise mechanisms involved 
in determining the distinct survival rates of these two 
molecular groups of patients, still remain to be elucidated 
and deserve further investigations.
Despite several classification models have 
been previously proposed which address the genomic 
heterogeneity of GBM [13, 14, 27] and identify tumors 
with different cellular origins, so far they have proven 
to be of limited prognostic value [34-36, 51] and/or 
difficult to be used in routine diagnostics due to the 
complexity of the information they require to classify 
GBM patients at diagnosis. In contrast, here we propose 
a relatively simple prognostic stratification model for 
GBM tumors based on their gene amplification profiles 
that might be easily implemented in routine laboratory 
diagnostics, and that will potentially contribute to a 
better management of the patients. In line with this, 
we have recently patented an array containing this 
combination of probes [52] to assess the above referred 
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Table 6: Clinical and biological characteristics of GBM patients from series 1 who were analyzed by single-
nucleotide polymorphism arrays in this study (n=80)
Case ID Age Gender KarnofskyIndex (%) Location
Brain 
hemisphere
Overall 
survival or 
follow-up
Exitus
Treatment
Type of 
surgery
Chemotherapy
GBM1 80 M ND Temporal L 6 Yes T ND
GBM2 75 M 80 Fronto-temporal R 22 Yes T Stupp
GBM3 61 F 90 Parietal R 83 Yes T Stupp
GBM4 73 M 100 Temporal L 19 Yes P Stupp
GBM5 38 M 90 Frontal R 15 Yes T Stupp
GBM6 49 F 60 Frontal R 30* No P Stupp
GBM7 41 M 40 Temporal R 11 Yes P Stupp
GBM8 57 M 90 Tempo-parietal R 6 Yes T Stupp
GBM9 72 M 90 Temporal R 28 No P Stupp
GBM10 62 M 100 Parietal R 28 No T Stupp
GBM11 71 M 80 Temporal R 27 Yes P Stupp
GBM12 50 F 100 Temporal R 13 Yes T Stupp
GBM13 72 F 70 Temporal R 9 Yes P Stupp
GBM14 78 F 100 Frontal R 6 Yes T -
GBM15 61 F 100 Frontal R 25 No T Stupp
GBM16 54 M 100 Fronto-parietal R 2 Yes T Stupp
GBM17 52 M 80 Frontal R 63 Yes P Stupp
GBM18 57 F 90 Temporal R 10 Yes P Stupp
GBM19 68 M 90 Occipital L 10 Yes T Stupp
GBM20 82 F 80 Frontal L 7 Yes T -
GBM21 77 M 70 Temporal R 6 Yes P -
GBM22 69 F 100 Frontal L 8 Yes T Stupp
GBM23 24 F 80 Frontal L 21 Yes P Stupp
G97 53 M 80 Temporal R 21 Yes T Stupp
G94 79 F 80 Temporal R 9 Yes P -
G93 63 M 80 Occipital R 29 Yes T Stupp
G92 54 F 80 Parietal R 15 Yes T Stupp
G91 73 F 60 Occipital R 13 Yes P Stupp
G90 57 F 60 Parietal L 5 Yes B -
G89 51 M 80 Temporal R 2 Yes P -
G88 71 M 80 Parietal R 8 Yes P Stupp
G87 45 M 80 Temporal L 16 Yes P Stupp/ Sequential
(Continued )
Oncotarget28097www.oncotarget.com
Case ID Age Gender KarnofskyIndex (%) Location
Brain 
hemisphere
Overall 
survival or 
follow-up
Exitus
Treatment
Type of 
surgery
Chemotherapy
G83 75 M 70 Temporal R 10 Yes P -
G82 78 M 70 Frontal R 2 Yes B -
G81 62 F 70 Frontal R 13 Yes P Stupp
G80 43 M 80 Frontal R 18 Yes T Stupp
G79 71 F 60 Occipital R 6 Yes B -
G73 78 F 60 Parietal L 4 Yes B -
G72 77 F 70 Temporal L 1 Yes P -
G71 66 F 60 Parietal R 10 Yes P Sequential
G70 56 F 80 Occipital L 21 Yes P Stupp
G68 72 M 70 Insular L 26 Yes T Stupp
G67 68 F 80 Parietal R 35 Yes P Stupp
G66 60 M 80 Occipital R 14 Yes T Stupp
G65 69 F 60 Parietal L 1 Yes P -
G64 57 M 60 Occipital L 8 Yes P Sequential
G63 61 F 60 Insular R 13 Yes P Sequential
G62 57 F 90 Occipital R 18 Yes T Stupp
G57 34 M 90 Frontal R 8 Yes T Stupp
G56 65 M 80 Frontal L 13 Yes P Stupp
G55 54 F 80 Frontal R 17 Yes P Stupp
G54 65 F 60 Parietal L 6 Yes P -
G53 74 M 60 Frontal L 29 Yes T Stupp
G52 56 M 90 Frontal L 21 Yes B Stupp
G51 60 M 60 Temporal R 2 Yes B -
G50 84 M 70 Temporal R 11 Yes P -
G46 62 M 60 Frontal L 3 Yes P -
G45 76 F 60 Temporal R 10 Yes P -
G44 48 M 80 Frontal L 22 Yes P PCV
G43 67 F 70 Temporal R 7 Yes P -
G42 67 M 80 Temporal R 2 Yes P -
G41 44 F 60 Frontal R 14 Yes B Sequential
G40 45 F 80 Frontal R 15 Yes P BCNU+TMZ
G39 70 F 50 Frontal R 18 Yes P Stupp
G37 70 M 80 Temporal R 32 Yes T Stupp
G35 50 F 80 Frontal L 2 Yes P -
G34 69 M 60 Temporal R 5 Yes B -
G31 71 F 90 Frontal R 7 Yes P -
(Continued )
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GAP, and that we hope can be commercially available 
for routine diagnostics soon.
MATERIALS AND METHODS
Patients and samples
Overall, 347 GBM tumors were studied. These 
included two groups of adult patients: the first group 
consisted of 80 caucasian GBM patients (group 1, series 
1) with histological diagnosis of primary GBM based on 
the WHO criteria (38 males and 42 females; mean age 
of 62±13 years, ranging from 24 to 84 years) (Table 6). 
Fifty-seven of these 80 patients (71%) were admitted to 
the University Hospital of Coimbra (Coimbra, Portugal) 
and their genomic data has been deposited in the genomic 
repository GEO (series code number: GSE42631) 
and 23 (29%) were from the University Hospital of 
Salamanca (Spain). Each patient from series 1 gave his/
her informed consent prior to entering the study, and the 
study was approved by the local Ethics Committees of 
both institutions, according to the Declaration of Helsinki. 
For each patient within this first group, tumor samples 
containing representative areas of (fresh) tumor tissues 
were obtained by surgical resection, immediately (<30 
min) snap-frozen in liquid nitrogen, and stored at -80ºC 
for further SNP-array studies; in parallel, a PB sample was 
also collected from each patient. Prior to the SNP-array 
studies, a section was cut from the stored tissue blocks and 
assessed by conventional histopathological procedures for 
its tumoral cell contents. Specimens with ≥75% tumoral 
cells, in the absence of significant contamination by 
normal brain parenchyma and tumoral necrosis, were 
selected for further DNA and RNA extraction.
The second group of GBM patients included 267 
unselected cases from 7 different series of GBM (series 
2 to 8; group 2) previously reported in the literature [15, 
24, 28–32]. Data from cases included in one of these 
series (series 4; n=15 cases) were kindly provided by 
Bralten et al [32], while data about the patients and 
tumor samples from the other six series was accessed 
from publicly available data bases – GSE19612 (series 
2; 24 cases); GSE19399 and GSE9635 (series 3; 104 and 
16 cases, respectively); GSE14804 (series 5; 12 cases); 
E-MEXP1330 (series 6, 53 cases); GSE10922 (series 7; 
13 cases) and GSE13021 (series 8; 30 cases)–.
DNA extraction and identification of copy 
number alterations by SNP-arrays
DNA from frozen tumor samples (n=80 tumors 
from series 1) was purified using the QIAamp DNA 
Mini Kit (Qiagen, Valencia, CA, USA), according to 
the instructions of the manufacturer. The yield and 
purity of the extracted DNA were determined using 
a NanoDrop-1000 spectrophotometer (Nano-Drop 
Technologies Inc, Wilmington, DE, USA), and they 
systematically showed absorbance (A) values >1.5 
at 260/230nm and ≥1.8 at 260/280nm wavelengths, 
respectively. DNA integrity was evaluated by 
conventional electrophoretic procedures in a 1% agarose 
gel. RNA extraction and cDNA synthesis were performed 
Case ID Age Gender KarnofskyIndex (%) Location
Brain 
hemisphere
Overall 
survival or 
follow-up
Exitus
Treatment
Type of 
surgery
Chemotherapy
G30 71 F 70 Temporal R 9 Yes B -
G29 49 F 80 Parietal L 12 Yes B Sequential
G25 68 M 80 Frontal L 6 Yes P Stupp
G23 50 F 70 Frontal R 14 Yes B Stupp
G17 30 F 90 Temporal R 67 Yes P Sequential
G15 79 M 80 Parietal L 5 Yes T Sequential
G14 69 F 70 Frontal R 0 Yes B -
G13 39 F 90 Frontal R 20 Yes P Sequential
G12 74 M 70 Temporal R 1 Yes B -
G10 35 F 80 Temporal L 15 Yes P Stupp
G8 67 F 90 Deep NA 9 Yes P Stupp
G6 70 F 80 Temporal R 19 Yes P Stupp
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following the standard operating procedures (SOPs) of the 
Spanish DNA Bank Carlos III (University of Salamanca, 
Salamanca, Spain) (http://www.bancoadn.org).
For the investigation of CNAs by SNP-arrays, 
DNA from frozen tumor tissues and their paired PB 
samples was used in order to exclude individual CNV 
due to germline SNPs, small insertions and deletions. 
Briefly, extracted DNA (250ng per array) was digested 
with restriction enzymes and ligated to the corresponding 
adaptors, following conventional Affymetrix procedures 
(Affymetrix Inc, Thermo-Fisher Scientific, Waltham, 
MA, USA). A generic primer that recognizes the adaptor 
sequence was used in triplicate, to amplify adaptor-
ligated DNA fragments via polymerase chain reaction 
(PCR). The amplified DNA was then fragmented, 
labeled, and hybridized to the corresponding SNP-
array (please see below). After hybridization, chips 
were washed in an Affymetrix Fluidics Station 450 
(Affymetrix) and the hybridized sequences were 
labeled using streptavidin-phycoerythrin, and assayed 
by fluorescence detection using a GeneChip Scanner 
3000 (Affymetrix). The allelotype at a locus was then 
determined based on probe-associated fluorescence 
intensity data for oligonucleotides complementary to 
the reference sequences that covered the corresponding 
SNP position.
In the test series (series 1), 4 different types of 
SNP-arrays were used. These included: i) the GeneChip 
Human Mapping 500K Array Set (n=35 tumors), which 
provides information about >500,000 SNPs according 
to the NCBI/hg19 assembly (262,264 SNPs in the 
Nsp array and 238,304 SNPs in the Sty array); ii) the 
Genome-Wide Human SNP Array 6.0 (n=22 cases), 
which contains probes for 906,600 SNPs and 945,826 
non-polymorphic probes featuring a total of >1.8 million 
probes (Affymetrix); and, iii) the CytoScan 750K and 
Cytoscan HD arrays (n=23 tumors) which contain probes 
for 200,436 SNPs and 743,304 non-polymorphic probes 
(Affymetrix). Data about DNA probes was analyzed 
with the Console Genotyping software (version 3.0.2; 
Affymetrix). In addition, the dChip 2010 software (http//
www.dchip.org; Dana Farber Cancer Institute, Boston, 
MA, USA) was used to calculate CNA values. To plot 
CNAs according to their chromosomal location, the 
Chromosome Analysis Suite (CHAS) was used. The Hg 
19 human genome sequence was used as reference to 
name the amplified genes, as defined by CNAs values > 
4.8 (arbitrary units) typically corresponding to > 7 DNA 
copies (in order to exclude polyploidies) [29].
For the validation series, data on 7 different SNP-
array chips (Affymetrix 50K, 100K, 250K and/or 500K 
SNP-arrays) previously reported by others [15, 23, 24, 
28–32] were used for the analysis of CNA. The number of 
common SNPs for the 100K and 500k arrays, and for the 
500K and cytoscan HD arrays, was of 21,144 and 65,535 
SNPs, respectively, for a total of around 11,000 SNPs in 
common to all SNPs-arrays used.
Mutational analyses
Analysis of IDH1 and IDH2 gene mutations was 
based on DNA extracted from formalin-fixed and paraffin-
embebed tissues (n=54) using the QIAamp DNA Mini kit 
(Qiagen, Germany) according to the instructions of the 
manufacture. Exon 4 DNA of both the IDH1 and the IDH2 
genes was amplified by PCR and sequenced on a capillary 
automated sequencer (CEQ 8000; Beckman-Coulter, 
Hialeah, FL, USA); mutational analysis of the sequence 
data was performed using the Sequencher, (version 4.7) 
software (Genes Codes, Ann Arbor, MI, USA). None of 
the 54 primary GBM cases analyzed showed IDH1 or 
IDH2 mutations.
Statistical analysis
The statistical significance of differences observed 
between groups was assessed by the Student T and 
the Mann-Whitney U tests, for parametric and non-
parametric (continuous) variables, respectively; for 
categorical variables, the X2 test was used. Overall, 
257 GBM who survived for >1 month after surgery and 
had a minimum follow-up of 18 months (for patients 
remaining alive) were included in OS analyses. Survival 
curves were plotted according to the method of Kaplan 
and Meier, and the (two-sided) log-rank test was used 
to assess the statistical significance of differences in OS 
among distinct groups of patients. Multivariate analysis 
of prognostic factors for OS was performed using the 
Cox stepwise regression model. In this part of the study, 
only those variables showing a significant association 
with RFS in the univariate analysis were included (Table 
5). P-values <0.05 were considered to be associated with 
statistical significance. For all statistical analysis, the 
SPSS software (SPSS 17.0, IBM SPSS, Armonk, NY, 
USA), was used.
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